From: The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
CTCAE grade | I | II | III | |||
---|---|---|---|---|---|---|
Symptom | Number (%) | Number (%) | Number (%) | |||
Hand-foot skin reaction | 10 | (22.2) | 15 | (33.3) | 12 | (26.7) |
Rash | 19 | (42.2) | 5 | (11.1) | 2 | (4.44) |
Diarrhea | 17 | (37.8) | 4 | (8.89) | 1 | (2.22) |
Hair loss | 17 | (37.8) | 2 | (4.44) | 2 | (4.44) |
Hypertension | 15 | (33.3) | 7 | (15.6) | 3 | (6.67) |
Fatigue | 22 | (48.9) | 3 | (6.67) | 0 | (0) |
Anorexia | 12 | (26.7) | 2 | (4.44) | 0 | (0) |
Nausea | 11 | (24.4) | 1 | (2.22) | 0 | (0) |
Depression | 9 | (20) | 0 | (0) | 0 | (0) |
Muscle aches | 14 | (31.1) | 0 | (0) | 0 | (0) |